The initial trial, which will involve 1,000 participants, will begin in Belgium, followed shortly by testing in the U.S. Researchers will evaluate the vaccine candidate’s safety and ability to produce an immune response.
J&J is also in talks with the National Institutes of Health to roll out an expansive phase 3 trial that could start in late September, in which researchers would analyze the vaccine candidate’s ability to protect against COVID-19. The drugmaker told The Wall Street Journal it could have an answer about the vaccine’s efficacy by the end of the year.
If trials are successful, J&J could make the vaccine available early next year. It plans to manufacture up to 1 billion doses of the shot by the end of 2021.
More articles on pharmacy:
Moderna COVID-19 vaccine spurs immune response, initial data shows
CVS fined for understaffing, prescription errors in Oklahoma
South Carolina drugmaker funnels $215 million into vaccine production center
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
